Ksb Limited has informed the Exchange about Transcript
KSB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
KSB Limited shared the transcript of its Q2 CY2025 investor meet, with presentations from MD Rajeev Jain, CFO Mahesh Bhave, and business heads covering the Nuclear, Solar, and core pump businesses. The company highlighted consistent growth: Revenue CAGR of 16%, PAT CAGR of 20%, and EBITDA CAGR of 18%, with ROCE at 23.42%. H1 2025 order intake stood at ₹17,381 million, and total orders in hand were ₹26,969 million as of June 2025, including ₹1,313 crore in nuclear orders (Kaiga 5&6, Kudankulam breakthrough, and a European export order). Solar business has grown to ₹134.3 crore YTD with 13,227 cumulative systems. The nuclear opportunity pipeline is significant, with 8 reactors under construction, 10 more sanctioned, and a 100 GW target by 2047. Non-nuclear, non-solar growth has been 12-14% versus market growth of 8-9%, led by water, building services, firefighting, navy, and oil & gas exports to the US and Middle East.
Positive for shareholders: Strong order book visibility (₹2,700 crore), healthy return ratios, and a clear multi-year growth runway in nuclear and solar segments. However, solar working capital (currently over 120 days) and delays in nuclear test bed readiness for the first two pump invoicings are near-term watchpoints.